-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Procaps Group (NASDAQ:PROC) Shares Gap Up to $4.73
Procaps Group (NASDAQ:PROC) Shares Gap Up to $4.73
Procaps Group S.A. (NASDAQ:PROC – Get Rating) shares gapped up before the market opened on Thursday . The stock had previously closed at $4.73, but opened at $5.15. Procaps Group shares last traded at $5.13, with a volume of 300 shares trading hands.
Procaps Group Trading Up 5.7 %
The stock's 50-day moving average is $6.10 and its 200 day moving average is $7.08.
Get Procaps Group alerts:Procaps Group (NASDAQ:PROC – Get Rating) last announced its quarterly earnings data on Monday, November 14th. The company reported $0.22 EPS for the quarter, beating analysts' consensus estimates of $0.13 by $0.09. Procaps Group had a net margin of 13.82% and a negative return on equity of 243.60%. The firm had revenue of $110.40 million for the quarter, compared to the consensus estimate of $123.90 million. As a group, equities analysts anticipate that Procaps Group S.A. will post 0.12 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in PROC. Millennium Management LLC grew its position in Procaps Group by 15.9% during the second quarter. Millennium Management LLC now owns 101,430 shares of the company's stock valued at $945,000 after purchasing an additional 13,908 shares in the last quarter. Citadel Advisors LLC bought a new stake in Procaps Group in the second quarter worth approximately $263,000. Finally, State Street Corp bought a new stake in Procaps Group in the third quarter worth approximately $89,000. 0.95% of the stock is owned by hedge funds and other institutional investors.About Procaps Group
(Get Rating)
Procaps Group SA develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory.
Featured Articles
- Get a free copy of the StockNews.com research report on Procaps Group (PROC)
- Is The Great Alibaba Recovery About To Begin?
- KB Home, Another Reason To Shed Home Building Stocks
- Is Wendy's Stock Uptrend Set To Continue?
- Altria Group Stock, Is Time is Running Out?
- Why Did the JinkoSolar Stock Price Rally 45%?
Receive News & Ratings for Procaps Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Procaps Group and related companies with MarketBeat.com's FREE daily email newsletter.
Procaps Group S.A. (NASDAQ:PROC – Get Rating) shares gapped up before the market opened on Thursday . The stock had previously closed at $4.73, but opened at $5.15. Procaps Group shares last traded at $5.13, with a volume of 300 shares trading hands.
預測集團股份有限公司(NASDAQ:PROC-獲取評級)股票在星期四開市之前突破。該股票之前已收盤 4.73 美元,但以 5.15 美元開盤。延期集團股票最後成交價為 5.13 美元,成交量為 300 股。
Procaps Group Trading Up 5.7 %
加工集團交易上升 5.7%
The stock's 50-day moving average is $6.10 and its 200 day moving average is $7.08.
該股票的 50 天移動平均線為 6.10 美元,其 200 日移動平均線為 7.08 美元。
Procaps Group (NASDAQ:PROC – Get Rating) last announced its quarterly earnings data on Monday, November 14th. The company reported $0.22 EPS for the quarter, beating analysts' consensus estimates of $0.13 by $0.09. Procaps Group had a net margin of 13.82% and a negative return on equity of 243.60%. The firm had revenue of $110.40 million for the quarter, compared to the consensus estimate of $123.90 million. As a group, equities analysts anticipate that Procaps Group S.A. will post 0.12 EPS for the current fiscal year.
普科集團(NASDAQ:PROC-獲取評級)上週一宣布了其季度盈利數據,週一,11 月 14 日。該公司報告了本季每股收益 0.22 美元,擊敗了分析師對 0.13 美元的共識估計,達到 0.09 美元。博佳集團的淨利潤率為 13.82%,負股本回報率為 243.60%。該公司本季度的收入為 110.40 億美元,與共識估計為 123.90 億美元相比。作為一個集團,股票分析師預計 Procaps Group S.A. 將在當前財政年度過帳 0.12 每股盈利。
Institutional Inflows and Outflows
機構流入和流出
About Procaps Group
關於程程集團
(Get Rating)
(取得評分)
Procaps Group SA develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory.
Procaps 集團 SA 在全球開發、生產和銷售醫藥解決方案。該公司在各種治療領域制定、製造和銷售品牌處方藥,包括女性護理產品、止痛、皮膚護理、消化系統健康、生長和發育、心臟科、視力保健、中樞神經系統和呼吸系統。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Procaps Group (PROC)
- Is The Great Alibaba Recovery About To Begin?
- KB Home, Another Reason To Shed Home Building Stocks
- Is Wendy's Stock Uptrend Set To Continue?
- Altria Group Stock, Is Time is Running Out?
- Why Did the JinkoSolar Stock Price Rally 45%?
- 獲取有關博康集團(PROC)的研究報告的免費副本
- 阿里巴巴大復甦即將開始嗎?
- KB 首頁, 另一個原因擺脫家庭建築股票
- 溫迪的股票上漲趨勢將繼續嗎?
- 奧特利亞集團股票,時間已經不多了嗎?
- 為什麼金科太陽能股價上漲 45%?
Receive News & Ratings for Procaps Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Procaps Group and related companies with MarketBeat.com's FREE daily email newsletter.
接收有關 Procaps 集團每日的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收 Procaps 集團和相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧